PRGN-2009 plus Pembrolizumab

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151PGENPhase 2Recruiting2026-11-11Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.